



KENNY C. GUINN
Governor

STATE OF NEVADA
DEPARTMENT OF HUMAN RESOURCES
DIVISION OF HEALTH CARE FINANCING AND POLICY
NEVADA MEDICAID

MICHAEL J. WILLDEN
Director

CHARLES DUARTE
Administrator

NOTICE OF OPEN PUBLIC MEETING

The Division of Health Care Financing and Policy (DHCFP), Pharmacy and Therapeutics Committee, will conduct a public meeting on **January 26, 2006** beginning at **1:00 p.m.** at the following location:

**Legislative Building
Room 2134
401 S. Carson St.
Carson City, NV**

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Nancy Davis at: 775-684-3715 or email ndavis@dhcfp.state.nv.us in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Below is an agenda of all items scheduled to be considered. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.

Public comment is limited to 5 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

AGENDA

- I. Call to Order and Roll Call
- II. *Review and Approval of October 26th Meeting Minutes
- III. Central Nervous System: ADHD/Stimulants/Non-Stimulants - Consideration of New Agent - Focalin XR® (Dexmethylphenidate Extended Release)
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- IV. Inhaled Corticosteroids - Consideration of New Agent - Asmanex Twisthaler® (mometasone furoate)
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

1100 E. William Street, Suite 102, Carson City, Nevada 89701
(775) 684-3600

- V. Ophthalmic Quinolones- New Drug Class to be Considered
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- VI. Ophthalmic Antihistamines-New Drug Class to be Considered
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- VII. Nasal Calcitonins- New Drug Class to be Considered
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- VIII. Injectable Immunomodulators-New Drug Class to be Considered
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- IX. Removal of Erectile Dysfunction Drugs from Preferred Drug List due to Congressional Action to Discontinue Federal Funding for these Agents
 - A. Presentation by DHCFP/First Health Services
 - B. Public Comment
 - C. *Committee Discussion and Action

- X. Review of Next Meeting Location, Date, and Time

- XI. Public Comment

- XII. *Adjournment

*** Denotes items, including subparts, on which an action may be taken.**

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (dhcfp.state.nv.us).

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.